Literature DB >> 22071223

Nanoliposome-mediated FL/TRAIL double-gene therapy for colon cancer: in vitro and in vivo evaluation.

Nian-feng Sun1, Qing-yi Meng, Ai-ling Tian, San-yuan Hu, Rui-hua Wang, Zhao-xuan Liu, Li Xu.   

Abstract

OBJECTIVE: To investigate the therapeutic effects of cationic nanoliposome-mediated gene therapy combined with immunotherapy for colon cancer treatment.
METHODS: Recombinant plasmids containing green and red fluorescent protein reporter genes were constructed using gene cloning methods. Gene-carrying cationic nanoliposomes were prepared based on the electrostatic adherence principle and then transfected into dendritic cells (DC), which were transplanted into colon cancer cells.
RESULTS: Recombinant plasmids containing green or red fluorescent protein reporter genes were successfully constructed by gene cloning and confirmed by restriction enzyme digestion and sequencing. Gene-carrying cationic nanoliposomes were transfected into colon cancer cells, and good gene expression was detected. A better level of apoptosis was observed in the combined group of tyrosine kinase receptor 3 ligand (FL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), while the lowest level was detected in the control group. The parameters in the FL and TRAIL groups were between the above-mentioned combined group.
CONCLUSION: Cationic nanoliposomes have the advantage of being gene carriers. The joint therapeutic effects of the two genes are superior to those of a single gene. Gene therapy combined with immunotherapy has significant implications for cancer treatment.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22071223     DOI: 10.1016/j.canlet.2011.10.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

Review 1.  Breast cancer proteome takes more than two to tango on TRAIL: beat them at their own game.

Authors:  Ammad Ahmad Farooqi; Sundas Fayyaz; Muhammad Tahir; Muhammed Javed Iqbal; Shahzad Bhatti
Journal:  J Membr Biol       Date:  2012-08-17       Impact factor: 1.843

2.  Therapeutic nanosystems for oncology nanomedicine.

Authors:  A S Gonçalves; A S Macedo; E B Souto
Journal:  Clin Transl Oncol       Date:  2012-07-27       Impact factor: 3.405

Review 3.  Role of nanotechnology and gene delivery systems in TRAIL-based therapies.

Authors:  George E Naoum; Fady Tawadros; Ammad Ahmad Farooqi; Muhammad Zahid Qureshi; Sobia Tabassum; Donald J Buchsbaum; Waleed Arafat
Journal:  Ecancermedicalscience       Date:  2016-08-01

Review 4.  TRAIL-based gene delivery and therapeutic strategies.

Authors:  Hui-Hai Zhong; Hui-Yuan Wang; Jian Li; Yong-Zhuo Huang
Journal:  Acta Pharmacol Sin       Date:  2019-08-23       Impact factor: 6.150

Review 5.  Application of liposomes in drug development--focus on gastroenterological targets.

Authors:  Jian-Xin Zhang; Kun Wang; Zheng-Fa Mao; Xin Fan; De-Li Jiang; Min Chen; Lei Cui; Kang Sun; Sheng-Chun Dang
Journal:  Int J Nanomedicine       Date:  2013-04-08

6.  Theranostic implications of nanotechnology in multiple sclerosis: a future perspective.

Authors:  Ajay Vikram Singh; Manish Khare; W N Gade; Paolo Zamboni
Journal:  Autoimmune Dis       Date:  2012-12-30

7.  Development of Doxorubicin-Loaded Magnetic Silica-Pluronic F-127 Nanocarriers Conjugated with Transferrin for Treating Glioblastoma across the Blood-Brain Barrier Using an in Vitro Model.

Authors:  Geetha B Heggannavar; Chinmay G Hiremath; Divya D Achari; Vishwas G Pangarkar; Mahadevappa Y Kariduraganavar
Journal:  ACS Omega       Date:  2018-07-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.